{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:38:05Z","timestamp":1793813885011,"version":"4.6.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Cluster headache, characterized by bouts of excruciating pain attacks, detrimentally affects health and quality of life. Eptinezumab is an anticalcitonin gene-related peptide monoclonal antibody approved for migraine prevention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of eptinezumab in the preventive treatment of episodic cluster headache.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This double-blind, placebo-controlled, randomized (1:1) clinical trial (Eptinezumab in Participants With Episodic Cluster Headache [ALLEVIATE]) was conducted between December 2020 and October 2023. Results are from the initial 4-week randomized phase. The study took place at 64 sites across Europe, the US, and Japan. Included were adults (aged 18-75 years) with a history of episodic cluster headache for 1 or more years (with bouts lasting \u22656 weeks when untreated) and previous acute and preventive medication use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Eptinezumab, 400 mg, or placebo (intravenous infusion).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was the change from baseline in the number of weekly attacks in weeks 1\u2009to\u20092. Safety was assessed using treatment-emergent adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 628 total participants screened, 320 entered the second screening period, and 231 met eligibility criteria. Of the 231 participants randomized (eptinezumab, n\u2009=\u2009118; placebo, n\u2009=\u2009113), 215 (93%) completed the placebo-controlled period. The participant mean (SD) age was 44 (11) years, and 178 of 229 were male (78%). At baseline, the mean (SD) weekly attacks were 15.2 (8.1) in the eptinezumab group and 15.7 (8.3) in the placebo group. There was no statistically significant difference between eptinezumab and placebo in the change from baseline in the number of weekly attacks over weeks 1\u2009to\u20092 (least-squares mean [SE], \u22124.0 [0.93] vs \u22124.6 [0.89]; between-group difference, 0.7; 95% CI, \u22121.3 to 2.6; <jats:italic>P<\/jats:italic>\u2009=\u2009.50). More eptinezumab-treated participants achieved 50% or greater response vs placebo over week 2 (50.9% [54 of 106] vs 37.3% [41 of 110]; odds ratio [OR], 1.77; 95% CI, 1.03-3.07; <jats:italic>P <\/jats:italic>=.04), week 3 (62.5% [65 of 104] vs 43.8% [49 of 112]; OR, 2.26; 95% CI, 1.30-3.97; <jats:italic>P <\/jats:italic>=.004), and week 4 (66.7% [68 of 102] vs 50.5% [54 of 107]; OR, 2.14; 95% CI, 1.21-3.83; <jats:italic>P<\/jats:italic> =.009). Eptinezumab showed numerically larger improvements than placebo for 75% or greater response, average daily pain scores, and across other patient-reported outcomes. Treatment-emergent adverse events occurred in 25.0% of patients (28 of 112) receiving eptinezumab and 26.5% of patients (31 of 117) receiving placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among adults with episodic cluster headache, eptinezumab did not significantly reduce the number of attacks vs placebo, although it was associated with numerically higher responder rates and improvements in average daily pain and patient-reported outcomes. Eptinezumab was generally well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04688775\">NCT04688775<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.1317","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:31:32Z","timestamp":1747654292000},"page":"706","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and Safety of Eptinezumab in Episodic Cluster Headache"],"prefix":"10.1001","volume":"82","author":[{"given":"Rigmor H.","family":"Jensen","sequence":"first","affiliation":[{"name":"Danish Headache Center, Department of Neurology, Rigshospitalet\u2013Glostrup, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[{"name":"Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy"},{"name":"IRCCS C. Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[{"name":"The New England Institute for Neurology and Headache, Stamford, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Charles","sequence":"additional","affiliation":[{"name":"UCLA Goldberg Migraine Program, Department of Neurology, David Geffen School of Medicine at UCLA, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[{"name":"UCLA Goldberg Migraine Program, Department of Neurology, David Geffen School of Medicine at UCLA, University of California, Los Angeles"},{"name":"NIHR King\u2019s Clinical Research Facility and Headache Group, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta H.","family":"Snoer","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Krog Josiassen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Borgen Linander","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neli","family":"Boneva","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi250026r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd edition.","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"noi250026r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/25158163221096866","article-title":"Patient-identified burden and unmet needs in patients with cluster headache: An evidence-based qualitative literature review.","volume":"5","author":"Freeman","year":"2022","journal-title":"Cephalalgia Rep"},{"issue":"1","key":"noi250026r3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/head.14021","article-title":"Cluster headache is one of the most intensely painful human conditions: results from the International Cluster Headache Questionnaire.","volume":"61","author":"Burish","year":"2021","journal-title":"Headache"},{"issue":"6","key":"noi250026r4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/practneurol-2018-002124","article-title":"Managing cluster headache.","volume":"19","author":"Wei","year":"2019","journal-title":"Pract Neurol"},{"issue":"6","key":"noi250026r5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1468-2982.2008.01592.x","article-title":"The incidence and prevalence of cluster headache: a meta-analysis of population-based studies.","volume":"28","author":"Fischera","year":"2008","journal-title":"Cephalalgia"},{"issue":"10","key":"noi250026r6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11916-021-00979-8","article-title":"Cluster headache: clinical characteristics and opportunities to enhance quality of life.","volume":"25","author":"Grinberg","year":"2021","journal-title":"Curr Pain Headache Rep"},{"issue":"9","key":"noi250026r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024231201577","article-title":"Epidemiology, burden and clinical spectrum of cluster headache: a global update.","volume":"43","author":"Kim","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"noi250026r8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-022-01427-7","article-title":"The economic and personal burden of cluster headache: a controlled cross-sectional study.","volume":"23","author":"Petersen","year":"2022","journal-title":"J Headache Pain"},{"key":"noi250026r9","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.4103\/aian.AIAN_17_18","article-title":"Treatment of cluster headache.","volume":"21","author":"Kingston","year":"2018","journal-title":"Ann Indian Acad Neurol"},{"issue":"10","key":"noi250026r10","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1111\/ene.15956","article-title":"European Academy of Neurology guidelines on the treatment of cluster headache.","volume":"30","author":"May","year":"2023","journal-title":"Eur J Neurol"},{"issue":"1","key":"noi250026r11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-023-01660-8","article-title":"Current treatment options for cluster headache: limitations and the unmet need for better and specific treatments\u2014a consensus article.","volume":"24","author":"Lund","year":"2023","journal-title":"J Headache Pain"},{"issue":"4","key":"noi250026r12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/head.14292","article-title":"Challenges and complexities in designing cluster headache prevention clinical trials: a narrative review.","volume":"62","author":"Dodick","year":"2022","journal-title":"Headache"},{"issue":"7","key":"noi250026r13","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1212\/01.wnl.0000267319.18123.d3","article-title":"Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy.","volume":"69","author":"Cohen","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"noi250026r14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10194-010-0289-x","article-title":"Cardiac safety in cluster headache patients using the very high dose of verapamil (=720 mg\/day).","volume":"12","author":"Lanteri-Minet","year":"2011","journal-title":"J Headache Pain"},{"issue":"2","key":"noi250026r15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"noi250026r16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/brain\/117.3.427","article-title":"Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies.","volume":"117","author":"Goadsby","year":"1994","journal-title":"Brain"},{"issue":"2","key":"noi250026r17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","article-title":"Trial of galcanezumab in prevention of episodic cluster headache.","volume":"381","author":"Goadsby","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"noi250026r18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","article-title":"Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment.","volume":"40","author":"Dodick","year":"2020","journal-title":"Cephalalgia"},{"issue":"1","key":"noi250026r22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","article-title":"Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide.","volume":"374","author":"Garcia-Martinez","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"noi250026r24","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","article-title":"Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine.","volume":"8","author":"Baker","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"23","key":"noi250026r25","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial.","volume":"325","author":"Winner","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"noi250026r26","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1177\/03331024221120266","article-title":"Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache.","volume":"42","author":"Schoenen","year":"2022","journal-title":"Cephalalgia"},{"issue":"11","key":"noi250026r27","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomized, double-blind, placebo-controlled, exploratory phase 2 trial.","volume":"13","author":"Dodick","year":"2014","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi250026r28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0333102419837154","article-title":"Calcitonin gene\u2013related peptide and disease activity in cluster headache.","volume":"39","author":"Snoer","year":"2019","journal-title":"Cephalalgia"},{"issue":"1","key":"noi250026r30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures.","volume":"27","author":"Hurst","year":"2004","journal-title":"J Manipulative Physiol Ther"},{"issue":"6","key":"noi250026r31","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)65105-4","article-title":"Development and validation of the sleep impact scale for insomnia.","volume":"10","author":"Crawford","year":"2007","journal-title":"Value in Health"},{"issue":"10","key":"noi250026r32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new 5-level version of EQ-5D (EQ-5D-5L).","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"5","key":"noi250026r34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument.","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"noi250026r35","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from 3 multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"noi250026r36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/00401706.1971.10488811","article-title":"Mean square error of prediction as a criterion for selecting variables.","volume":"13","author":"Allen","year":"1971","journal-title":"Technometrics"},{"key":"noi250026r37","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2147\/JPR.S305066","article-title":"Impact of galcanezumab on total pain burden: a post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study in patients with episodic cluster headache.","volume":"14","author":"Andrews","year":"2021","journal-title":"J Pain Res"},{"issue":"12","key":"noi250026r38","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102413484989","article-title":"Randomized trial on episodic cluster headache with an angiotensin II receptor blocker.","volume":"33","author":"Tronvik","year":"2013","journal-title":"Cephalalgia"},{"issue":"8","key":"noi250026r39","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/0333102419856607","article-title":"Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a meta-analysis.","volume":"39","author":"de Coo","year":"2019","journal-title":"Cephalalgia"},{"issue":"6","key":"noi250026r40","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/archneur.59.6.990","article-title":"Intranasal civamide for the treatment of episodic cluster headaches.","volume":"59","author":"Saper","year":"2002","journal-title":"Arch Neurol"},{"issue":"10","key":"noi250026r41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024241291597","article-title":"ANODYNE study: A double-blind randomized trial of greater occipital nerve block of methylprednisolone and lignocaine versus placebo as a transitional preventive treatment for episodic cluster headache.","volume":"44","author":"Chowdhury","year":"2024","journal-title":"Cephalalgia"},{"issue":"6","key":"noi250026r42","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1046\/j.1468-29821995.1506452.x","article-title":"Guidelines for controlled trials of drugs in cluster headache.","volume":"15","author":"Lipton","year":"1995","journal-title":"Cephalalgia"},{"issue":"10","key":"noi250026r43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaneurol.2018.1675","article-title":"Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial.","volume":"75","author":"Vollesen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi250026r44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024231223970","article-title":"Reduced plasma calcitonin gene-related peptide level identified in cluster headache: a prospective and controlled study.","volume":"44","author":"Petersen","year":"2024","journal-title":"Cephalalgia"},{"key":"noi250026r45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10072-020-04639-4","article-title":"Cluster headache and TACs: state of the art.","volume":"41","author":"Giani","year":"2020","journal-title":"Neurol Sci"},{"issue":"1","key":"noi250026r46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-024-01732-3","article-title":"Commentary on 2022 guidelines on clinical trial design in cluster headache and further suggestions.","volume":"25","author":"Medrea","year":"2024","journal-title":"J Headache Pain"},{"issue":"10","key":"noi250026r47","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","article-title":"Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing.","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"issue":"1","key":"noi250026r48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-021-01227-5","article-title":"Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.","volume":"22","author":"Smith","year":"2021","journal-title":"J Headache Pain"},{"key":"noi250026r29","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"noi250026r19","unstructured":"EU Clinical Trials Register. A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study comparing the efficacy and safety of 2 dose regimens (intravenous\/subcutaneous and subcutaneous) of TEV-48125 vs placebo for the prevention of chronic cluster headache. Version 1.3, August 2019. Accessed September 6, 2024. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-003278-42\/results"},{"key":"noi250026r20","unstructured":"EU Clinical Trials Register. A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study comparing the efficacy and safety of 2 dose regimens (intravenous\/subcutaneous and subcutaneous) of TEV-48125 vs placebo for the prevention of episodic cluster headache. Version 1, May 2020. Accessed September 16, 2024. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-003278-42\/results"},{"key":"noi250026r21","unstructured":"Eli Lilly and Company. EMGALITY [package insert]. Accessed October 31, 2024. https:\/\/emgality.lilly.com\/"},{"key":"noi250026r23","unstructured":"Lundbeck Seattle BioPharmaceuticals Inc. VYEPTI [package insert]. Accessed October 31, 2024. https:\/\/www.vyeptihcp.com\/"},{"key":"noi250026r33","unstructured":"Reilly Associates. WPAI:GH V2.0. Accessed September 16, 2024. http:\/\/www.reillyassociates.net\/WPAI_GH.html"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2833817\/jamaneurology_jensen_2025_oi_250026_1751558086.7123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:00:29Z","timestamp":1752505229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2833817"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.1317","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}